MedTrace Logo

Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects

NCT04686591 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2021-03-09

No results posted yet for this study

Summary

Study to Assess the Absorption, Metabolism, and Excretion of \[14C\]AZD9977 after a Single-Dose Oral Administration

Conditions

Interventions

DRUG

AZD9977 capsule 50 mg

100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capusles)

DRUG

[14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)

One 100 µg dose of \[14C\]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)

DRUG

[14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)

One 100 mg dose of \[14C\]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)

Sponsors & Collaborators

  • Quotient Sciences

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Somasekhara Menakuru, MBBS, MS, MRCS, DPM · Quotient Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-21
Primary Completion
2021-02-04
Completion
2021-02-04
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04686591 on ClinicalTrials.gov